Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00089167 · ClinicalTrials.gov registry record · Phase 2
Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00089167: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00089167 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00089167, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs such as melphalan, thalidomide, and dexamethasone may be effective in treating patients with primary systemic amyloidosis. PURPOSE: This phase II trial is studying how well giving melphalan together with thalidomide and dexamethasone works in treating patients with primary systemic amyloidosis.
Interventions
- DRUG dexamethasone
- DRUG melphalan
- BIOLOGICAL filgrastim
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-05 |
| Phase | Phase 2 |
What the finished NCT00089167 record still lists
NCT00089167 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which dexamethasone is the first listed.
NCT00089167 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00089167 about?
NCT00089167 is a clinical study titled "Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis". RATIONALE: Drugs such as melphalan, thalidomide, and dexamethasone may be effective in treating patients with primary systemic amyloidosis. PURPOSE: This phase II trial is studying how well giving melphalan together with thalidomide and dexamethasone works in treating patients with primary systemic...
What is the current status of trial NCT00089167?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-05.
What interventions are being tested in trial NCT00089167?
The interventions under investigation include: dexamethasone (DRUG), melphalan (DRUG), filgrastim (BIOLOGICAL), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00089167?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia